With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for ...

Two med-tech companies focused on pulmonary embolism overcame their own blockages to commercialization this week. Inquis ...

CSPC Pharmaceutical Group Ltd. announced June 13 that it struck a potential $5.33 billion deal with Astrazeneca plc to ...

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...

(NASDAQ:SRPT) plunged to $19.91, down $16.27, or almost 45%, on word of a second death by acute liver failure (ALF) with Elevidys (delandistrogene moxeparvovec), the approved gene therapy for patients ...

Supernus Pharmaceuticals Inc. is buying Sage Therapeutics Inc. for about $795 million. The deal brings Supernus, already firmly in the CNS market, the only U.S. FDA-approved oral treatment for ...

Focused on promoting well-being amongst children with neurodivergence, Reset Moves Pty Ltd. created app-based games to help children not only focus with greater clarity, but also to better help them ...

Myrio Therapeutics Pty Ltd. is set to advance lead product PHOX2B PC-CAR T (PHOX2B peptide-centric chimeric antigen receptor autologous T cells) into clinical trials for relapsed neuroblastoma ...

Systemic lupus erythematosus is a chronic autoimmune disease in which immune cells invade various organs and unleash harmful inflammatory responses. Estrogen may contribute to the condition, which ...

Researchers at the Olivia Newton-John Cancer Research Institute and collaborators have developed a new anti-HER2 monoclonal antibody, mAb104, which targets a conformationally exposed, tumor-specific ...

Therapies involving B-cell depletion targeting CD19 or BCMA have shown efficacy in the treatment of B-cell malignancies. Recently, this approach has shown efficacy in the treatment of autoimmune ...

Researchers from the Institute for Basic Science of Korea and collaborating institutions have designed a new class of peptide-based inhibitors targeting a crucial interface within the SARS-CoV-2 ...